USCOM LIMITED — Regulatory Filings 2021

Sep 22, 2021

ASX MEDIA RELEASE

BP+ 94% Effective for AF Screening in Primary Care

SYDNEY, Australia, Thursday 23[rd] September 2021: Uscom Limited (ASX code: UCM) (the Company or Uscom ) today released details of a study confirming the high accuracy of the Uscom BP+ central blood pressure monitor for detection of the dangerous cardiac rhythm abnormality Atrial Fibrillation (AF) in a primary care setting. This results confirms that BP+ suprasystolic oscillometry is 94% effective for detection of AF in home care environments and may be used as a screening investigation.

Summary:

AF is a common cardiac dysrhythmia occurring in approximately 40m adults worldwide. However AF is associated with significant mortality and morbidity from stroke and heart failure and is often undiagnossed. The presence of AF may warrant the use of prophylactic anticoagulation, which is also associated with additional complications, making the accurate and cost effective detection of AF an important health screening procedure. This study compared Uscom BP+ suprasystolic oscillometric detection of AF with a 12 lead ECG interpreted by a senior cardiology consultant and found an accuracy of 90% for BP+ measures with an overall effectiveness of 94%. Concurrent comparison of a hand held phone with a dual lead ECG attached for detection of AF demonstrated an accuracy of 73%. The Uscom BP+ examination can be performed in approximately 60 seconds by a technician while the 12 lead ECG takes in the order of 15-30 minutes and requires a consultant cardiologist for interpretation.

Report:

The BP+ suprasystolic monitor is a specialised technology for diagnosis and therapeutic guidance in hypertension and vascular health. The accurate detection of AF as part of the current BP examination using the BP+ suprasystolic oscillometer expands the utility and application of the technology, and simplifies the primary care assessment of cardiovascular risk. The BP+ technology is simple to operate and provides rapid and accurate results, from 58 measures of blood pressure and cardiovascular performance, compared to the 6 presented in current simple BP monitors.

Commentary:

Uscom Executive Chairman, Professor Rob Phillips said “Uscom is a leader in medical technology, and the BP+ Suprasystolic oscillometric monitor is another life-saving innovation from Uscom Limited. This new technology is a leap forward in the detection and management of hypertension and stroke prevention. Incremental steps shift practice and outcomes in medical care, and this is Uscom’s mission. It has taken a number of years for us to refine this technology, and our BP+ combined with the BP+ Reporter, is now being proven as a clinical advancement in these critical and common conditions.. The BP+ and BP+ Reporter have CE, and recently, NMPA regulatory approval, and are now being prepared for high volume sales in China and Europe as we prepare for the US FDA.”

Uscom manufactures and markets the USCOM 1A , the Uscom BP+ and BP+ Reporter , the Uscom SpiroSonic digital ultrasonic spirometry technologies and SpiroReporter , and the VENTITEST and VENTITEST-S ultrasonic ventilator calibration devices for optimising respiratory device performance.

References:

Sluyter JD, Scragg R, Ofanoa M, et al. Atrial fibrillation detection in primary care during blood pressure measurements and using a smartphone cardiac monitor. Scientific Reports 2021; 11:17721, DOI.org/10.1038/s41598-021-97475-1 Lippi G, et al. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021 Feb; 16(2):217-221. DOI:10.1177/17474930198897870

Uscom Limited (ABN 35 091 028 090) Suite 2, Level 8, 66 Clarence Street, Sydney, NSW, 2000, Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au

ASX MEDIA RELEASE

About Uscom

Uscom Limited (UCM) : An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A : A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric infectious diseases and sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+ : A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary BP+ Reporter , an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

Uscom SpiroSonic digital multi-path ultrasonic spirometers : High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone apps and proprietary SpiroSonic software, SpiroReporter , with wireless interfacing to provide remote telemonitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, occupational lung disease and monitoring of pulmonary therapeutic compliance.

VENTITEST digital ultrasonic ventilator testing solution is a new system for testing ventilators. All ventilators require calibration to maintain the accuracy with which they measure the pressure, flow and volume of air they deliver. VENTITEST and VENTITEST-S, based on advanced SpiroSonic technology provides a testing solution that provides for simple and accurate testing, archiving, analysis and reporting to optimise ventilation performance.

For more information, please visit: www.uscom.com.au

Uscom Contacts Rob Phillips Chairman rob@uscom.com.au

Brett Crowley Company Secretary

This announcement is approved for release to the ASX by the Board of Uscom Limited.

Uscom Limited (ABN 35 091 028 090) Suite 2, Level 8, 66 Clarence Street, Sydney, NSW, 2000, Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au